30 Apr 2014 07:01
BEXIMCO PHARMACEUTICALS LTD.
30th April, 2014
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Ltd. (or "Company"; LSE-AIM: BXP) today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 29th April, 2014 has decided the following:
1. | To recommend the approval of the Financial Statements for the year ended 31 December 2013 | : | The Audited Financial Statements for the year ended 31 December 2013 has been approved. The full accounts are expected to be announced by 14th May 2014 |
2. | Date & Time of 38th AGM of the Company for the year 2013 | : | 21 June, 2014 at 10.30 am |
3. | Venue of AGM | : | Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh |
4. | Proposed Dividend for the year ended 31 December 2013 | : | 5% Stock Dividend (i.e. 5 shares for every 100 shares held) and 10% Cash Dividend (i.e. Tk. 1 per share) |
5. | Record date | : | 18 May, 2014 |
6. | Net Asset Value as at 31 December 2013 | : | Taka 19,775,552,465 |
7. | Net Asset Value per Share as at 31 December 2013 | : | Taka 56.45 |
8. | Earnings per share (EPS) for the year ended 31 December 2013 | : | Taka 4.01 |
9. | Net Operating Cash Flow per share for the year ended 31 December 2013 | : | Taka 6.08 |
For further information please visit www.beximco-pharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing DirectorTel: +880 2 861 9151, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 8618220-1, Ext 10140
Daniel Stewart & Company (NOMAD and Broker)
Emma Earl
Paul Shackleton
Tel: +44 (0)20 7776 6550
FTI Consulting
Simon Conway / Victoria Foster-MitchellTel: +44 (0)20 7327 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.
Beximco Pharma (BXP)